Journal Information
Vol. 37. Issue 8.
Pages 349-357 (August 2001)
Share
Share
Download PDF
More article options
Vol. 37. Issue 8.
Pages 349-357 (August 2001)
Full text access
Recomendaciones ALAT sobre la exacerbación infecciosa de la EPOC
Visits
12553
M. Miravitlles
Corresponding author
marcm@separ.es

Correspondencia: Servicio de Neumología. Hospital General Vall d'Hebron P.° Vall d'Hebron, 119-129. 08035 Barcelona
, Grupo de Trabajo de la Asociación Latinoamericana del Tórax (Alat) *
This item has received
Article information
Full text is only aviable in PDF
Bibliografía
[1.]
P. Ball.
Epidemiology and treatment of chronic bronchitis ant its exacerbations.
Chest, 108 (1995), pp. 43S-52S
[2.]
B.R. Celli, G.L. Snider, J. Heffner, B. Tiep, I. Ziment, B. Make, et al.
Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 152 (1995), pp. S77-S120
[3.]
N.M. Siafakas, P. Vermeire, N.B. Pride, P. Paoletti, J. Gibson, P. Howard, et al.
ERS consensus statement. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). A consensus statement of the European Respiratory Society (ERS).
Eur Respir J, 8 (1995), pp. 1398-1420
[4.]
British Thoracic Society.
BTS guidelines for the management of chronic obstructive pulmonary disease.
Thorax, 52 (1997), pp. 4-28
[5.]
T. Montemayor Rubio, Y. Alfajeme Mediavilla, C. Escudero Bueno, J. Morera Prat, L. Sánchez Agudo.
Normativa sobre diagnóstico y tratamiento de la enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol, 32 (1996), pp. 285-301
[6.]
M.S. Balter, R.H. Hyland, D.E. Low, P.M. Renzi, A.C. Braude, P.J. Cole, et al.
Recommendations on the management of chronic bronchitis. A practical guide for Canadian physicians.
Can Med Ass J, 151 (1994), pp. 7-23
[7.]
N.R. Anthonisen, J. Manfreda, C.P.W. Warren, E.S. Hershfield, G.K.M. Harding, N.A. Nelson.
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.
Ann Intern Med, 106 (1987), pp. 196-204
[8.]
D.M. Mannino, C. Brown, G.A. Giovino.
Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiple-cause mortality data.
Am J Respir Crit Care Med, 156 (1997), pp. 814-818
[9.]
V. Sobradillo, M. Miravitlles, R. Gabriel, C.A. Jiménez-ruiz, C. Villasante, J.F. Masa, et al.
Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study.
Chest, 118 (2000), pp. 981-989
[10.]
A.M.B. Menezes, C.G. Victoria, M. Rigatto.
Prevalence and risk factors for chronic bronchitis in Pelotas, RS, Brazil: a population-based study.
Thorax, 49 (1994), pp. 1217-1221
[11.]
R. Sansores, J.R. Pérez-padilla.
Enfermedad pulmonar obstructiva crónica.
Un problema mundial, un enfoque en México. Piensa,
[12.]
Estadísticas Vitales. Mortalidad, Estados Unidos Mexicanos, México DF, 1997.
Inegi, Ssa/Dgei, (1998),
[13.]
D. Maldonado, F. Bolívar, A. Caballero, A. Casas, J. Roa, C. Salgado.
Sociedad Colombiana de Neumología y Cirugía de Tórax. Recomendaciones para el diagnóstico y manejo del paciente con enfermedad pulmonar obstructiva crónica (EPOC).
Rev Colomb Neumol, 9 (1997), pp. 1-39
[14.]
Report n.° 12681-CH. Chile. The adult health policy change. Human resources operation division. Country department. Latin America and the Caribbean Region.
Document of the World Bank, (10 de noviembre de 1994),
[15.]
J. Christopher, L. Murray, A. López.
Global Health Statistics.
Harvard School of Public Health editores,
[16.]
Secretaría de Salud, Dirección General de Epidemiología, Instituto Mexicano de Psiquiatría.
Encuesta Nacional de las Adicciones, tabaco,
[17.]
L. Arango, J.M. Luna.
Tabaquismo en Guatemala,
[18.]
Department of Health and Human Services. Centers for Diseases Control. Smoking and health in the Americas. USA. DHHS publication n.° CDC 92-8420
[19.]
B. Ostro, J.M. Sánchez, C. Aranda, G. Eskaland.
Air pollution and mortality: results from a study in Santiago, Chile.
J Exp Environ Epidemiol, 6 (1996), pp. 97-114
[20.]
D.P. Tashkin, R. Detals, M. Simmonds, H. Liu, A.H. Coulson, J. Sayre, et al.
The UCLA population studies of chronic obstructive respiratory diseases. Impact of air pollution and smoking on annual change in forced expiratory volume in one second.
Am J Respir Crit Care Med, 149 (1994), pp. 1209-1217
[21.]
R. Pérez-padilla, J. Regalado, S. Vadel, P. Pare, R. Chapela, R. Samons, et al.
Exposure to biomass smoke and chronic airway diseases in Mexican women.
Am J Respir Crit Care Med, 154 (1996), pp. 701-706
[22.]
R.J. Dennis, D. Maldonado, S. Norman, E. Baena, G. Martínez.
Woodsmoke exposureand risk for chronic obstructive airwas disease among women.
Chest, 109 (1996), pp. 115-119
[23.]
J. Luna, L. Arango.
Bronquitis crónica secundaria a la exposición al humo de leña. Archivos Unidad Pulmonar. Hospital Roosevelt.
Rev Med Intern Guatemala, 3 (1996), pp. 16-20
[24.]
D.J. Hendrick.
Occupation and chronic obstructive pulmonary disease (COPD).
Thorax, 51 (1996), pp. 947-955
[25.]
S.O. Shaheen, D.J.P. Barker, A.W. Shiell, F.J. Crocker, G.A. Wield, S.T. Holgate.
The relationship between pneumonia in early childhood and impaired lung function in late adult life.
Am J Respir Crit Care Med, 149 (1994), pp. 616-619
[26.]
P. Hodgins, P.K. Henneberger, M.-.L. Wang, E.L. Petsonk.
Bronchial responsiveness and five-year FEV1 decline: a study in miners and nonminers.
Am J Respir Crit Care Med, 157 (1998), pp. 1390-1396
[27.]
A.J. Sandford, T.D. Weir, P.D. Paré.
Genetic risk factors for chronic obstructive pulmonary disease.
Eur Respir J, 10 (1997), pp. 1380-1391
[28.]
M. Miravitlles, R. Vidal, J. De Gracia.
Enfisema por déficit de alfa- 1-antitripsina. Situación actual y nuevas perspectivas para el tratamiento.
Arch Bronconeumol, 28 (1992), pp. 296-302
[29.]
M. Miravitlles, C. Mayordomo, M. Artés, L. Sánchez-Agudo, F. Nicolau, J.L. Segú.
on behalf of the EOLO Group Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice.
Respir Med, 93 (1999), pp. 173-179
[30.]
E. Monsó, J. Ruiz, A. Rosell, J. Monterola, J. Fiz, J. Morera, et al.
Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush.
Am J Respir Crit Care Med, 152 (1995), pp. 1316-1320
[31.]
J. Eller, A. Ede, T. Schaberg, M.S. Niederman, H. Mauch, H. Lode.
Infective exacerbations of chronic bronchitis. Relation between bacteriologic etiology and lung function.
Chest, 113 (1998), pp. 1542-1548
[32.]
M. Miravitlles, C. Espinosa, E. Fernández-Laso, J.A. Martos, J.A. Maldonado, M. Gallego.
and Study Group of Bacterial Infection in COPD. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD.
Chest, 116 (1999), pp. 40-46
[33.]
S.S. Richter, A.B. Brueggemann, H.K. Huynh, P.R. Rhomberg, E.M. Wingert, R. Flamm, et al.
A 1997-1998 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US institutions.
Intern J Antimicrob Agents, 13 (1999), pp. 99-107
[34.]
M. Guzmán-Blanco, J.M. Casellas, H.S. Sader.
Bacterial resistance to antimicrobial agents in Latin America. The giant is awakening.
Infect Dis Clin North Am, 14 (2000), pp. 67-81
[35.]
D. Felmingham, R.N. Gruneberg.
The Alexander Project 1996- 1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections.
J Antimicrob Chemother, 45 (2000), pp. 191-203
[36.]
R. Wise, D. Honeybourne.
Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract.
Eur Respir J, 14 (1999), pp. 221-229
[37.]
R.A. Stockley, C. O'Brien, A. Pye, S.L. Hill.
Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.
Chest, 117 (2000), pp. 1638-1645
[38.]
P.R. Murray, J.A. Washington.
Microscopic and bacteriologic analysis of expectorated sputum.
Mayo Clin Proc, 50 (1975), pp. 339-344
[39.]
D.E. Niewoehner, M.L. Erbland, R.H. Deupree, D. Collins, N.J. Gros, R.W. Light, et al.
Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease.
N Engl J Med, 340 (1999), pp. 1941-1947
[40.]
L. Davies, R.M. Angus, P.M.A. Calverley.
Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial.
Lancet, 354 (1999), pp. 456-460
[41.]
L. Allegra, C. Grassi, E. Grossi, E. Pozzi, F. Blasi, D. Frigerio, et al.
Ruolo degli antibiotici nel trattamento delle riacutizzazioni della bronchite cronica: risultati di uno studio italiano multicentrico.
Ital J Chest Dis, 45 (1991), pp. 138-148
[42.]
S.G. Adams, J. Melo, M. Luther, A. Anzueto.
Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD.
Chest, 117 (2000), pp. 1345-1352
[43.]
S. Saint, S. Bent, E. Vittinghoff, D. Grady.
Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-ananlysis.
Jama, 273 (1995), pp. 957-960
[44.]
M. Miravitlles, C. Murio, T. Guerrero.
on behalf of the DAFNE Study Group. Factors associated with relapse after treatment of acute exacerbations of chronic bronchitis.
Eur Respir J, 17 (2001), pp. 928-933
[45.]
J.T. MacFarlane, A. Colville, A. Guion, R.M. MacFarlane, D.H. Rose.
Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community.
Lancet, 341 (1993), pp. 511-515
[46.]
P. Ball, J.M. Harris, D. Lowson, G. Tillotson, R. Wilson.
acute infective exacerbations of chronic bronchitis.
Q J Med, 88 (1995), pp. 61-68
[47.]
G.J. Huchon, G. Gialdroni-Grassi, P. Léophonte, F. Manresa, T. Schaberg, M. Woodhead.
Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey.
Eur Respir J, 9 (1996), pp. 1590-1595
[48.]
P. Davey, D. Rutherford, B. Graham, B. Lynch, M. Malek.
Repeat consultations after antibiotic prescribing for respiratory infection: a study in one general practice.
Br J Gen Pract, 44 (1994), pp. 509-513
[49.]
N.A. Dewan, S. Rafique, B. Kanwar, H. Satpathy, K. Ryschon, G.S. Tillotson, et al.
acute exacerbation of COPD. Factors associated with poor treatment outcome.
Chest, 117 (2000), pp. 662-671
[50.]
M. Miravitlles, J.L. Segú, T. Guerrero, R. Gisbert.
Murio C (Grupo DAFNE). Estudio farmacoeconómico del tratamiento antibiótico de las agudizaciones de la bronquitis crónica en atención primaria.
Aten Primaria, 25 (2000), pp. 153-159
[51.]
W.A. Craig.
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.
Clin Infect Dis, 26 (1998), pp. 1-12
[52.]
M. Miravitlles, C. Murio, T. Guerrero, J.L. Segú.
Costs derived from management of acute exacerbations of chronic bronchitis and COPD.
Eur Respir J, 14 (1999), pp. 115
[53.]
G.H. Murata, M.S. Gorby, C.O. Kapsner, T.W. Chick, A.K. Halperin.
A multivariate model for predicting hospital admissions for patients with decompensated chronic obstructive pulmonary disease.
Arch Intern Med, 152 (1992), pp. 82-86
[54.]
R. Antonelli Incalzi, L. Fuso, M. De Rosa, F. Forastiere, E. Rapiti, B. Nardecchia, et al.
Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease.
Eur Respir J, 10 (1997), pp. 2794-2800
[55.]
E. Prescott, P. Lange, J. Vestbo.
Chronic mucus hypersecretion in COPD and death from pulmonary infection.
Eur Respir J, 8 (1995), pp. 1333-1338
[56.]
C. Landbo, E. Prescott, P. Lange, J. Vestbo, T.P. Almidal.
Prognostic value of nutritional status in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 160 (1999), pp. 1856-1861
[57.]
R. Kessler, M. Faller, G. Fourgaut, B. Mennecier, E. Weitzenblum.
Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 159 (1999), pp. 158-164
[58.]
M. Miravitlles, T. Guerrero, C. Mayordomo, L. Sánchez-Agudo, F. Nicolau, J.L. Segú, Group on Behalf of the EOLO Study.
Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis.
Respiration, 67 (2000), pp. 495-501
[59.]
J.r. Connors AF, N.V. Dawson, C. Thomas, J.r. Harrel FE, N. Desbiens, W.J. Fulkerson, et al.
Outcomes following acute exacerbation of severe chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 154 (1996), pp. 959-967
[60.]
R. Wilson, R. Kubin, I. Ballin, K.M. Deppermann, H.P. Bassaris, P. Leophonte, et al.
Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.
J Antimicrob Chemother, 44 (1999), pp. 501-513
[61.]
S. Chodosh, A. Schreurs, G. Siami, H.W. Barkman, A. Anzueto, M. Shan, et al.
The efficacy of oral ciprofloxacin vs clarithromycin for the treatment of acute bacterial exacerbations of chronic bronchitis.
Clin Infect Dis, 27 (1998), pp. 730-738
[62.]
N. Soler, S. Ewig, A. Torres, X. Filella, J. González, A. Xaubet.
Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease.
Eur Respir J, 14 (1999), pp. 1015-1022
[63.]
S.W. Crooks, D.L. Bayley, S.L. Hill, R.A. Stockley.
Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4.
Eur Respir J, 15 (2000), pp. 274-280
[64.]
A. Bhowmik, T.A.R. Seemungal, R.J. Sapsford, J.A. Wedzicha.
Relation of suputum inflammatory markers to symptoms and lung function changes in COPD exacerbations.
Thorax, 55 (2000), pp. 114-120
[65.]
P. Bresser, T.A. Out, L. Van Alphen, H.M. Jansen, R. Lutter.
Airway inflamation in nonobstructive and obstructive chronic bronchitis with chronic Haemophilus influenzae airway infection.
Am J Respir Crit Care Med, 162 (2000), pp. 947-952
[66.]
A. Anzueto, J.A. Rizzo, R.F. Grosman.
The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis.
Clin Infect Dis, 28 (1999), pp. 1344-1345
[67.]
R.A. Stockley.
Role of bacteria in the pathogenesis and progression of acute and chronic lung infection.
Thorax, 53 (1998), pp. 58-62
[68.]
M. Miravitlles, C. Murio, T. Guerrero, J.L. Segú.
Tratamiento de la bronquitis crónica y la EPOC en atención primaria.
Arch Bronconeumol, 35 (1999), pp. 173-178
[69.]
S. Kesten, K.R. Chapman.
Physician perceptions and management of COPD.
Chest, 104 (1993), pp. 254-258
[70.]
M. Miravitlles.
Moxifloxacin: an antibiotic designed for use in the community.
Eur Respir Rev, 10 (2000), pp. 161-169
[71.]
N. Soler, A. Torres, S. Ewig, J. González, R. Celis, M. El-Ebiary, et al.
Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation.
Am J Respir Crit Care Med, 157 (1998), pp. 1498-1505
[72.]
K.L. Nichol, L. Baken, A. Nelson.
Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease.
Ann Intern Med, 130 (1999), pp. 397-403
[73.]
Prevention Centers for Disease Control and.
Prevention of pneumococcal disease. Recommendations of the Advisory Committee of Immunization Practices (ACIP).
Mmwr, 46 (1997), pp. 1-24

Integrantes del Grupo de Trabajo ALAT Coordinadores:A. Anzueto (EE.UU.) y J.R. Jardim (Brasil). Miembros del grupo:H. López, C. Luna y J. Antonio Mazzei (Argentina); J.C. Abreu de Oliveira y J. Pereira (Brasil); P. González y C. Lisboa (Chile); D. Maldonado y C. Torres (Colombia); S. Martínez Selmo (República Dominicana); M. Miravitlles, F. Rodríguez de Castro y A. Torres (España); J. Ramírez (EE.UU.); J.M. Luna (Guatemala); M. Díaz, R. Pérez Padilla, A. Ramírez y R. Sansores (México)

Copyright © 2001. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?